Professor Amit Nathwani is Chair of Rare Disease at LifeArc. He is renowned for his work in gene therapy with an impressive track record of developing cutting-edge, transformative treatments for patients living with a rare disease.
Currently the Head of Department of Haematology, University College London (UCL), Royal Free Campus and a Senior NIHR Investigator, his team was responsible for the first successful trial of gene therapy in an inherited bleeding disorder, Haemophilia B. He has applied these learnings to build the next generation of gene transfer technology. A serial innovator and entrepreneur, he has founded UCL spin-out companies, Freeline and NovalGen, and licensed technology to BioMarin.
Professor Nathwani has led nine first-in-human trials and secured over £50 million in competitive funding. His contributions have earned him major awards, including the Ham-Wasserman Award (ASH), ESGCT Outstanding Achievement Award, and UCL Enterprise Award. He has authored over 100 peer-reviewed publications and numerous patents.
